These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

648 related items for PubMed ID: 16332942

  • 1. Epoetin alfa versus darbepoetin alfa in chemotherapy-related anemia.
    Cersosimo RJ, Jacobson DR.
    Ann Pharmacother; 2006 Jan; 40(1):58-65; quiz 169-70. PubMed ID: 16332942
    [Abstract] [Full Text] [Related]

  • 2. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X, Long SR, Marder WD, Sullivan SD, Kallich J.
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness of darbepoetin alfa versus epoetin alfa for the treatment of chemotherapy induced anemia in patients with gynecologic malignancies.
    Case AS, Rocconi RP, Kilgore LC, Barnes MN.
    Gynecol Oncol; 2006 Jun; 101(3):499-502. PubMed ID: 16406064
    [Abstract] [Full Text] [Related]

  • 4. Phase III clinical trials with darbepoetin: implications for clinicians.
    Glaspy J.
    Best Pract Res Clin Haematol; 2005 Jun; 18(3):407-16. PubMed ID: 15792914
    [Abstract] [Full Text] [Related]

  • 5. A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.
    Schwartzberg LS, Yee LK, Senecal FM, Charu V, Tomita D, Wallace J, Rossi G.
    Oncologist; 2004 Jun; 9(6):696-707. PubMed ID: 15561813
    [Abstract] [Full Text] [Related]

  • 6. Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.
    Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.
    Pharmacoeconomics; 2006 Jun; 24(5):479-94. PubMed ID: 16706573
    [Abstract] [Full Text] [Related]

  • 7. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective.
    Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD.
    J Med Econ; 2008 Jun; 11(2):199-213. PubMed ID: 19450080
    [Abstract] [Full Text] [Related]

  • 8. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
    Molina M, García Hernández MA, Navarro MJ, Pérez Silva F, Cacho M, De Gracia MC.
    Nefrologia; 2004 Jun; 24(1):54-9. PubMed ID: 15083958
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice.
    Patton J, Reeves T, Wallace J.
    Oncologist; 2004 Jun; 9(4):451-8. PubMed ID: 15266098
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [Abstract] [Full Text] [Related]

  • 11. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 12. A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia.
    Schwartzberg L, Shiffman R, Tomita D, Stolshek B, Rossi G, Adamson R.
    Clin Ther; 2003 Nov; 25(11):2781-96. PubMed ID: 14693304
    [Abstract] [Full Text] [Related]

  • 13. Use and cost of erythropoiesis-stimulating agents in patients with cancer.
    Daniel G, Hurley D, Whyte JL, Willey V, Wilson M, Kallich J.
    Curr Med Res Opin; 2009 Jul; 25(7):1775-84. PubMed ID: 19505205
    [Abstract] [Full Text] [Related]

  • 14. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA, Harpe SH, Brophy GM.
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [Abstract] [Full Text] [Related]

  • 15. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
    Yang MC.
    Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
    [No Abstract] [Full Text] [Related]

  • 16. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
    Hoggard J, Crouch T, McMurray S, Levine M, Prathikanti R, Scarlata D, Audhya P.
    Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
    [Abstract] [Full Text] [Related]

  • 17. Darbepoetin alfa: new indication/new dosage. No proven advantage in chemotherapy-induced anaemia.
    Prescrire Int; 2005 Oct; 14(79):174-6. PubMed ID: 16285072
    [Abstract] [Full Text] [Related]

  • 18. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia.
    Glaspy J.
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):29-32. PubMed ID: 16925109
    [Abstract] [Full Text] [Related]

  • 19. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial.
    20030125 Study Group TrialUniversity of California Los Angeles School of Medicine, Los Angeles, CA 90095, USA. jglaspy@mednet.ucla.edu, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G.
    J Clin Oncol; 2006 May 20; 24(15):2290-7. PubMed ID: 16710026
    [Abstract] [Full Text] [Related]

  • 20. Effects of darbepoetin alfa administered every two weeks on hemoglobin and quality of life of patients receiving chemotherapy.
    Folloder J.
    Oncol Nurs Forum; 2005 Jan 19; 32(1):81-91. PubMed ID: 15660146
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.